Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp (symbol: BBLG) is a leading biotechnology firm focused on regenerative medicine orthobiologics. Originally a spin-off of the Musculoskeletal Transplant Foundation (MTF), Bone Biologics utilizes technology licensed from UCLA. The company was founded in 2004 in collaboration with professors from the University of California, Osaka University, and a USC surgeon. Acquired by MTF in 2006, MTF remains the major shareholder and primary funder.
Bone Biologics' core technology, UCB-1™, is a patented platform designed to facilitate superior bone growth. This technology has demonstrated remarkable success in large animal model studies, including sheep and rhesus monkeys, showing its capability in surpassing existing standards of care. The company believes that UCB-1™ can significantly improve outcomes in various surgical procedures involved in bone repair and regeneration.
The firm’s proprietary product, NELL-1, serves as a bone void filler and is positioned to revolutionize several surgical specialties. These include spinal surgery, general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics is headquartered in the United States and continues to pioneer healthcare solutions aimed at enhancing bone regeneration.
With its broad applications and promising results, Bone Biologics is at the forefront of developing innovative treatments that can aid numerous medical fields. The company’s commitment to excellence and continuous improvement makes it a noteworthy player in the biotechnology sector.
Bone Biologics (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, has appointed Phillip T. Meikle to its Board of Directors. Mr. Meikle brings over 30 years of commercial experience in the orthopedic and spine industry. He succeeds Don R. Hankey, who retired after seven years of service. The board remains at four directors.
Mr. Meikle was previously the president and CEO of Biosystems of New England, Inc., an orthopedic distribution company he founded in 1992 and sold to Stryker in 2019. He has been a consultant to Stryker Spine for the past five years. His company served as a distributor for Stryker Spine from 2002 to 2019 and for Medtronic Spine from 1992 to 2002.
Jeffrey Frelick, president and CEO of Bone Biologics, expressed enthusiasm about Mr. Meikle's appointment, citing his extensive experience with orthopedic and spine products as particularly valuable as the company develops NB1 for spinal fusion patients.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.
The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced a $2.1 million gross proceeds from the exercise of warrants. The company entered into a definitive agreement for the exercise of existing warrants to purchase 781,251 shares of common stock at $2.43 per share. In exchange, Bone Biologics will issue new unregistered warrants to purchase up to 1,562,502 shares of common stock at $2.00 per share.
The new warrants will have varying terms: half with a five-year term and half with an eighteen-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around August 2, 2024. Bone Biologics plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.
Bone Biologics (Nasdaq: BBLG) has commenced the first treatments in its pilot clinical study evaluating the NB1 bone graft device for spine fusion in patients with degenerative disc disease (DDD). The study, involving 30 patients, aims to assess the safety, effectiveness, fusion success, pain relief, functional improvement, and adverse events of NB1. The first two patients were treated in Australia. The U.S. FDA has reviewed and agreed upon the study's design, which could support a pivotal U.S. trial. CEO Jeffrey Frelick highlighted NB1's potential to address a $3 billion global spine fusion market.
FAQ
What is the current stock price of Bone Biologics (BBLG)?
What is the market cap of Bone Biologics (BBLG)?
What does Bone Biologics Corp (BBLG) specialize in?
What is UCB-1™ technology?
Which surgical specialties can benefit from Bone Biologics' technologies?
When was Bone Biologics Corp founded?
Who are the primary collaborators in founding Bone Biologics?
What is NELL-1?
Who is the major shareholder and primary funder of Bone Biologics?
Where is Bone Biologics Corp headquartered?
What makes Bone Biologics' UCB-1™ technology unique?
What is the goal of Bone Biologics' research and development?
